RT Journal Article
SR Electronic
T1 Dissecting the Genetic Architecture of Intracranial Aneurysms
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.30.23293390
DO 10.1101/2023.07.30.23293390
A1 Adkar, Shaunak S.
A1 Lynch, Julie
A1 Choi, Ryan B.
A1 Roychowdhury, Tanmoy
A1 Judy, Renae L.
A1 Paruchuri, Kaavya
A1 Go, Dong-Chuan
A1 Bamezai, Sharika
A1 Cabot, John
A1 Sorondo, Sabina
A1 Levin, Michael G.
A1 Milewicz, Dianna M.
A1 Willer, Cristen J.
A1 Natarajan, Pradeep
A1 Pyarajan, Saiju
A1 Chang, Kyong-Mi
A1 Damrauer, Scott
A1 Tsao, Phil
A1 Skirboll, Stephen
A1 Leeper, Nicholas J.
A1 Klarin, Derek
YR 2023
UL http://medrxiv.org/content/early/2023/08/05/2023.07.30.23293390.abstract
AB Background The genetic risk of intracranial aneurysm (IA) development has been ascribed largely to the genetic risk of smoking exposure and hypertension. However, the relationship of IA to other cardiovascular traits and the contribution of IA risk loci to aberrant gene programs within cerebrovascular cell types remains unclear.Methods We performed a genome-wide association study in the Million Veteran Program testing association of roughly 25 million DNA variants with unruptured IA (3,165 cases and 592,927 controls) in veterans of European, African, and Hispanic ancestries. This was meta-analyzed with publicly available summary statistics to yield a final cohort of 15,438 cases and 1,183,973 controls. Candidate causal genes were prioritized through expression quantitative trait loci colocalization, fine-mapping transcriptome wide association studies, and multi-trait colocalization. We constructed a cerebrovascular single nucleus RNA sequencing (snRNA-seq) dataset and integrated IA summary statistics to prioritize candidate causal cell types. We then constructed a polygenic risk score to identify patients at greater risk of developing IA.Results We identified five novel loci association with IA, increasing the number of known susceptibility loci to 22. At these susceptibility loci, we prioritized 16 candidate causal genes. Amongst other cardiovascular traits, we found a significant positive genetic correlation of IA with coronary artery disease and abdominal aortic aneurysm, and we identified 13 IA risk loci that colocalize with aneurysmal, atherosclerotic, and blood pressure traits. Integration of an IA gene set with human cerebrovascular snRNA-seq data revealed significant association with matrix-producing pericytes, smooth muscle cells (SMCs), and other mural subtypes. In addition, gene expression analysis revealed enrichment of several candidate genes within SMCs and pericytes. Finally, a high polygenic risk score (PRS) was significantly associated with IA across European (OR: 1.87, CI: 1.61-2.17, P = 8.8 × 10−17), African (OR: 1.62, CI: 1.19-2.15, P = 1.2 × 10−3), and Hispanic (OR: 2.28, CI: 1.47-3.38, P = 1.0 × 10−4) ancestries.Conclusion Here, we identify five novel loci associated with IA. Integration of summary statistics with cerebrovascular snRNA-seq reveals association of cell-types involved in matrix production. We constructed and validated a PRS that predicts IA, while controlling for demographic variables including smoking status, sex, and blood pressure. Taken together, our findings suggest that an intrinsic deficit in matrix production and vascular integrity may drive IA pathogenesis independent of systemic hypertension and smoking exposure.Competing Interest StatementP.N. reports grants from Amgen, Apple, AstraZeneca, Boston Scientic, and Novartis, is a consultant for Apple, AstraZeneca, Blackstone Life Sciences, Foresite Labs, geneXwell, Novartis, Roche / Genentech, and TenSixteen Bio, is a scientific co-founder of TenSixteen Bio, and spousal employment at Vertex, all unrelated to the present work. Derek Klarin is a senior scientific advisor for and accepts consulting fees from Bitterroot Bio, unrelated to the present work.Funding StatementThis research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by awards # I01- BX003362 (P.S.T. and K.-M.C.)/K2-CX001780 (S.M.D.)/IK2BX005759-01 (D.K), and the VA Informatics and Computing Infrastructure (VINCI) VA HSR RES 130457 (J.A.L.). SSA is supported by the NIH T32HL 98049-13. NJL is supported by the NIH R35HL 144475 and AHA EIA34770065. DK is additionally supported by AHA 23SCEFIA1153369.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The VA Central Institutional Review Board and Million Veteran Program Proposal and Publication Committee gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe full summary level association data from the MVP IA discovery analysis and meta-analysis from this manuscript will be available through dbGAP, accession code phs00167.v2.p1 upon publication.